Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024)

Inhibikase Therapeutics (IKT) has reported Capital Leases for 3 consecutive years, with $58330.0 the latest figure, recorded in Q1 2024.

• In Q1 2024, Capital Leases fell 67.25% year-over-year to $58330.0; the TTM figure through Mar 2024 stood at $58330.0 (down 67.25% YoY), while the FY2023 annual figure was $90124.0, down 56.13% from the prior year.
• Capital Leases fell to $58330.0 in Q1 2024 per IKT's latest filing, from $90124.0 in the prior quarter.
• Across five years, Capital Leases topped out at $232020.0 in Q3 2022 and bottomed at $58330.0 in Q1 2024.
• Historically, Capital Leases has averaged $147859.9 across 3 years, with a median of $149971.0 in 2023.
• Annual changes were most pronounced in 2023 — Capital Leases sank 47.84% — and 2024, when it sank 67.25%.
• Inhibikase Therapeutics' Capital Leases stood at $205451.0 in 2022, then plunged by 56.13% to $90124.0 in 2023, then slumped by 35.28% to $58330.0 in 2024.
• Business Quant data shows IKT's Capital Leases at $58330.0 in Q1 2024, $90124.0 in Q4 2023, and $121013.0 in Q3 2023.